Home › Free Stock Grades › RCUS
Arcus Biosciences, Inc. (RCUS) Stock Grade
RCUS · Healthcare
C
Market Cap
$3.1B
P/E Ratio
—
Revenue Growth (YoY)
-4.3%
Net Margin
-142.9%
Return on Equity
—
Dividend Yield
None
About Arcus Biosciences, Inc.'s fundamentals
Arcus Biosciences is a $3.1 billion biotechnology company currently operating at a loss, with a net margin of -142.9% reflecting significant spending on research and development that exceeds its revenue generation. The company experienced a year-over-year revenue decline of 4.3%, and it does not pay a dividend. As a pre-profitability biotech firm, traditional valuation metrics like P/E ratio and return on equity are not applicable.